PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27449698-3	2016	Here, we describe GS-6615, a selective inhibitor of late INa , already in clinical development for the treatment of long QT syndrome 3 (LQT3).	eleclazine	18-25	LOW QUALITY PROTEIN: alpha-internexin	Oryctolagus cuniculus	57-60	
27449698-4	2016	EXPERIMENTAL APPROACH: The effects of GS-6615 to inhibit late INa , versus other ion currents to shorten the ventricular action potential duration (APD), monophasic APD (MAPD) and QT interval, and decrease to the incidence of ventricular arrhythmias was determined in rabbit cardiac preparations.	eleclazine	38-45	LOW QUALITY PROTEIN: alpha-internexin	Oryctolagus cuniculus	62-65	
27449698-6	2016	KEY RESULTS: GS-6615 inhibited ATX-II enhanced late INa in ventricular myocytes (IC50  = 0.7 muM), shortened the ATX-II induced prolongation of APD, MAPD, QT interval, and decreased spatiotemporal dispersion of repolarization and ventricular arrhythmias.	eleclazine	13-20	LOW QUALITY PROTEIN: alpha-internexin	Oryctolagus cuniculus	52-55	
27449698-8	2016	In contrast to flecainide, GS-6615 had the minimal effects on peak INa .	eleclazine	27-34	LOW QUALITY PROTEIN: alpha-internexin	Oryctolagus cuniculus	67-70	
27449698-10	2016	CONCLUSIONS AND IMPLICATIONS: GS-6615 was a selective inhibitor of late INa , stabilizes the ventricular repolarization and suppresses arrhythmias in a model of LQT3.	eleclazine	30-37	LOW QUALITY PROTEIN: alpha-internexin	Oryctolagus cuniculus	72-75